In our study, mutant TET2, DNMT3A, ASXL1, and FLT3‐ITD showed inferior impacts on survival of AML patients, whereas NRAS mutation and CEBPAdm exhibited the opposite influence. Here, DNMT3A is linked to acute myeloid leukemia.